What is the Oncotype DX test, and how does its recurrence score help decide whether someone with early breast cancer nee

The Oncotype DX test is a genomic test that analyzes a sample of breast cancer tissue to look at the activity of a specific group of genes. These genes provide information about how a cancer is likely to behave and how it might respond to certain treatments.

It is primarily used for people diagnosed with early-stage, hormone receptor-positive (HR+), and HER2-negative breast cancer.

How the Recurrence Score Works

After the tissue sample is analyzed, the test provides a "Recurrence Score" (RS), which is a number between 0 and 100. This score helps doctors and patients make informed decisions about whether chemotherapy, in addition to hormone therapy, is likely to be beneficial.

• Low Recurrence Score (0–25): In many cases, research has shown that patients with a low score receive little to no benefit from adding chemotherapy to their hormone therapy. For these patients, hormone therapy alone is often recommended, allowing them to avoid the side effects of chemotherapy.
• High Recurrence Score (26–100): A higher score indicates that the cancer has a higher likelihood of recurring and that chemotherapy is more likely to provide a significant benefit in reducing that risk.

Why it is helpful

Before genomic tests like Oncotype DX, decisions about chemotherapy were based primarily on clinical factors such as tumor size, grade, and lymph node status. This often led to "over-treatment," where patients received chemotherapy even when it wouldn't significantly improve their long-term outcomes.

By providing a more personalized view of the tumor's biology, the Recurrence Score helps your medical team balance the potential benefits of chemotherapy against its risks and side effects, helping you make a decision tailored to your specific diagnosis.

Disclaimer: I am an AI, not a doctor. This information is for educational purposes and should not replace professional medical advice. Please discuss your specific test results and treatment options directly with your oncologist.